Ikena Oncology Inc

IKNA | $1.3 3.18% 3.08% 330K

(0.0% 1d) (-11.3% 1m) (-72.5% 1y) (0.0% 2d) (7.3% 3d) (3.9% 7d) (92.48% volume)
Earnings Calendar: 2023-11-06
Market Cap: $ 62,735,544
https://www.ikenaoncology.com
Sec Filling | Patents | 67 employees

Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing five programs that include four product candidates in either clinical development or IND-enabling studies: IK-930, a TEAD inhibitor targeting the Hippo signaling pathway; an ERK5 inhibitor program targeting the KRAS signaling pathway; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme; and IK-007, an EP4 receptor antagonist. Ikena has entered into a global strategic collaboration with Bristol-Myers Squibb Company for its IK-175 and IK-412 programs.

cancer

add to watch list Paper trade email alert is off

Press-releases

Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
IKNA | $1.3 3.18% 3.08% 330K

Manufacturing

| 0.0% | O: 1.5% H: 0.0% C: -6.67%

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
IKNA | $1.3 3.18% 3.08% 330K

Manufacturing

| -8.9% | O: -1.37% H: 4.17% C: -3.47%
year financial results

Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference
Published: 2024-02-27 (Crawled : 13:00) - globenewswire.com
IKNA | $1.3 3.18% 3.08% 330K

Manufacturing

| -12.5% | O: 1.32% H: 1.3% C: -1.95%
conference health care

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
Published: 2024-02-21 (Crawled : 21:00) - globenewswire.com
IKNA | $1.3 3.18% 3.08% 330K

Manufacturing

| 0.0% | O: 2.26% H: 4.41% C: -2.21%
medical

Ikena Oncology Outlines Key Priorities and Provides Corporate Updates
Published: 2024-01-18 (Crawled : 21:00) - globenewswire.com
IKNA | $1.3 3.18% 3.08% 330K

Manufacturing

| -18.9% | O: 3.66% H: 4.71% C: -10.59%
key

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results
Published: 2023-11-09 (Crawled : 12:00) - globenewswire.com
IKNA | $1.3 3.18% 3.08% 330K

Manufacturing

| -67.8% | O: -5.08% H: 0.0% C: -66.07%
ik-930 positive trial financial results

Ikena Oncology to Present at Multiple November 2023 Investor Conferences
Published: 2023-11-07 (Crawled : 13:00) - globenewswire.com
IKNA | $1.3 3.18% 3.08% 330K

Manufacturing

| -66.41% | O: 1.64% H: 7.89% C: 2.36%

Ikena Oncology to Participate in September 2023 Investor Conferences
Published: 2023-09-05 (Crawled : 12:00) - globenewswire.com
IKNA | $1.3 3.18% 3.08% 330K

Manufacturing

| -72.41% | O: -0.21% H: 0.21% C: -2.7%
MS | News | $90.66 0.44% 0.07% 8.1M

Finance

| 5.62% | O: 0.01% H: 0.0% C: 0.0%

Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update
Published: 2023-08-10 (Crawled : 12:00) - globenewswire.com
IKNA | $1.3 3.18% 3.08% 330K

Manufacturing

| -68.33% | O: -0.71% H: 12.83% C: 8.87%
update financial results

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
Published: 2023-08-07 (Crawled : 11:00) - globenewswire.com
IKNA | $1.3 3.18% 3.08% 330K

Manufacturing

| -73.02% | O: 0.61% H: 1.01% C: -8.06%

See all